Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap6.87B
Enterprise Value7.63B
P/E Ratio36.03
PEG Ratio-0.85
Price/Sales Ratio2.16
Price/Book Ratio1.13
Enterprise/Revenue2.34
Enterprise/EBITDA12.54

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin0.07
Operating Margin0.12
AD

Management Effectiveness

Return On Assets0.02
Return On Equity0.03

Income Statement

Revenue5.48B
Revenue/Share3.69
Gross Profit1.74B
EBITDA846.59M
Net Income349.49M
Diluted EPS0.24

Balance Sheet

Total Cash3.5B
Total Cash/Share2.39
Total Debt2.79B
Total Debt/Equity0.23
Current Ratio2.15
Book Value Per Share8.33

Price History

52-Week Change-21.08
52-Week High7.26
52-Week Low3.74
Moving Average 50 Days4.54
Moving Average 200 Days5.15

Statistics

Average Volume387,932
Shares Outstanding3.38B
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0.14
Trailing Annual Dividend Yield1.55
Payout Ratio0.12
Last Split FactorN/A
Last Split DateN/A
AD